NEO

AI MemoPost-earnings T+3

NeoGenomics

As of 2026-07-31/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-31 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 earnings showed durable growth and raised FY2026 guidance • 2026-07-28

Base target: $19 / p=50% prob

Biggest risk

Clinical volume increased only 2%, while reported GAAP net income was just $2 million and benefited from an $11 million debt-extinguishment gain. The $316 million convertible offering, pending MolDx approvals, reimbursement sensitivity, and the DOJ settlement add execution, dilution, and regulatory risks. [#SEC-8K-2026-07-28]

Invalidation

Break below $13 or thesis failure.

What would change my mind?

The earnings release supports a constructive operating thesis: double-digit revenue growth, 26% NGS growth, improving adjusted EBITDA, higher average revenue per clinical test, and raised full-year guidance. The advanced-testing mix and pending reimbursement opportunities could support further growth. [#SEC-8K-2026-07-28]

Research note

Recommendation

—

Confidence

medium

As of

2026-07-31

Base target

$19

p=50%

Bull target

$21

p=25%

Bear target

$13

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Raised guidance becomes the next execution benchmark
Advanced oncology testing and reimbursement expansion
The earnings release supports a constructive operating thesis: double-digit revenue growth, 26% NGS growth, improving adjusted EBITDA, higher average revenue per clinical test, and raised full-year guidance.

BearKey bullets

Clinical volume growth may not keep pace with pricing and mix benefits.
Convertible notes may increase dilution or create future capital-structure pressure.
Execution of the raised full-year guidance is not yet validated by post-print analyst revisions.

WatchKey bullets

Q2 earnings showed durable growth and raised FY2026 guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $19 (p=50%)

Target spread vs base: +14% / -28%

Scenario probabilities

Bull Target: $21 (p=25%)Base Target: $19 (p=50%)Bear Target: $13 (p=25%)

Commentary

The primary earnings release materially improved the operating narrative, but the packet does not provide verified post-print analyst revisions, target changes, or a clean multi-day market-reaction series. Social coverage is unavailable. Sentiment is therefore positive but best treated as medium-confidence monitoring rather than a fully confirmed rerating thesis.

As of 2026-07-31 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Raised guidance becomes the next execution benchmark
Advanced oncology testing and reimbursement expansion

Scenarios

Bull Target (Scenario probability)

$21 / p=25% prob

Base Target (Scenario probability)

$19 / p=50% prob

Bear Target (Scenario probability)

$13 / p=25% prob

Analysis 2026-07-31 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-07-28
Q2 earnings showed durable growth and raised FY2026 guidance
Second-quarter revenue rose 11% year over year to $202 million, clinical services grew 14%, NGS grew 26%, and adjusted EBITDA increased 36%. Management also raised full-year 2026 revenue and adjusted EBITDA guidance. [#SEC-8K-2026-07-28] [#8-K-2026-07-28]
Prob 85.00% • Move 8.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Raised guidance becomes the next execution benchmark
2026-08-31
The post-earnings setup now depends on converting the raised full-year outlook into sustained revenue growth and margin expansion. The packet does not show delayed analyst estimate or target revisions, so this remains a monitoring catalyst rather than a confirmed rerating signal.
Prob 70% • Move 5% • Priced-in 60%

Long-term Catalysts

Months to a year

Advanced oncology testing and reimbursement expansion
2026-12-31
Growth is shifting toward advanced testing, while the company continues commercial execution around oncology and has submitted additional RaDaR ST evidence to MolDx. The third submission remains pending approval, leaving meaningful execution and reimbursement optionality but limited near-term certainty. [#SEC-8K-2026-07-28] [#SEC-8K-2026-04-28]
Prob 65% • Move 15% • Priced-in 45%

Risks

Clinical volume growth may not keep pace with pricing and mix benefits.
Convertible notes may increase dilution or create future capital-structure pressure.
Execution of the raised full-year guidance is not yet validated by post-print analyst revisions.
RaDaR ST reimbursement approvals remain pending, creating regulatory and commercialization uncertainty.
Reported profitability remains modest and partly reflects a non-operating debt-extinguishment gain.

Peers

Symbol	Summary
ATRC	Closest same-sector market-cap candidate in the packet, but AtriCure is a procedural-device business and is not a close operating match for oncology diagnostics.
BSX	Large diversified medtech comparator with stronger scale and broader device exposure; useful for sector context but a loose valuation peer for NeoGenomics.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-31

Loading AI feed…

Symbol

Summary

ATRC

Closest same-sector market-cap candidate in the packet, but AtriCure is a procedural-device business and is not a close operating match for oncology diagnostics.

BSX

Large diversified medtech comparator with stronger scale and broader device exposure; useful for sector context but a loose valuation peer for NeoGenomics.